Phase 3 Completed N=136 Treatment

Genotropin Study Assessing Use of Injection Pen

Growth Hormone Deficiency · idiopathic short stature

Source: ClinicalTrials.gov NCT00965484 ↗

Enrolled (actual)

136

Serious AEs

0.0%

Results posted

Dec 2010

Primary outcomePrimary: Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin Pen® — 73.68 percentage of dyads

Summary

Assessment of Genotropin patient and caregiver (Dyad) perception of convenience and preference of Genotropin injection pen. Patients already on genotropin will be asked to use a genotropin pen for 2 months. Patient and caregiver will be asked to complete a questionnaire at baseline and 2 months.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin Pen®	73.68	—
SECONDARY Percentage of Dyads Reporting no Preference or Preference for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin Pen®	65.15	—
SECONDARY Percentage of Dyads Reporting New Genotropin Mark VII Injection Pen Easier to Use Compared to Pre-study Experience With the Genotropin Pen®	63.16	—
SECONDARY Percentage of Dyads Reporting New Genotropin Mark VII Injection Pen Preferable Compared to Pre-study Experience With the Genotropin Pen®	59.85	—

Eligibility Criteria

Inclusion Criteria

Age 8-18 years
Using genotropin pen for at least 3 months prior to study enrollment
Compliance with genotropin treatment

Exclusion Criteria

Medical conditions that can affect participation in study
Insufficient command of English language to understand questionnaire
Using other growth hormone device and not Genotropin pen

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00965484). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.